Summary
The issue of whether metastases result from the random survival of cells released from a primary tumor or from the selective growth of specialized tumor subpopulations endowed with metastatic properties is important to our understanding of the metastatic process and to the development of therapeutic modalities against metastatic disease. We have found that the tumor cells populating spontaneous metastases are more metastatic than the cells populating the parent neoplasm, clearly indicating that metastasis is selective and not random. The selective nature of metastasis is a consistent observation, however, only when tumor cells are obtained from spontaneous metastases from mice bearing heterogenous, poorly metastatic tumors. Tumor cells from spontaneous metastases from mice bearing tumors that have been selected for metastatic potential or that are homogeneous (cloned) do not differ significantly in metastatic potential from tumor cells populating the parent tumor. Thus, under some conditions the process of metastasis can appear random. Although tumor cells from different individual metastases may be homogeneous with regard to a metastatic phenotype, they may be heterogeneous with regard to their sensitivity to chemotherapeutic agents. Thus, although metastasis selects for metastatic variants, resulting in the population of metastatic foci with tumor cells endowed with metastatic properties, it does not appear to select for phenotypes irrelevant to the process of metastasis such as sensitivity to therapeutic agents.
Similar content being viewed by others
References
Dunn TB: Morphology of mammary tumors in mice. In: Homburger F, Fisheman NH (eds) Physiopathology of cancer. New York, Karger, 1959, pp 38–84.
Foulds L: The histologic analysis of mammary tumors of mice. I. Scope of investigations and general principles of analysis. J Natl Cancer Inst (7): 701–712, 1956.
Foulds L: The histologic analysis of mammary tumors in mice. II. The histology of responsiveness and progression. The origins of tumors. J Natl Cancer Inst (17): 713–754, 1956.
Foulds L: The histologic analysis of mammary tumors of mice. III. Organoid tumors. J Natl Cancer Inst (17): 755–782, 1956.
Foulds L: The histologic analysis of mammary tumors of mice. IV. Secretion. J Natl Cancer Inst (17): 783–802, 1956.
Henderson JS, Rous P: The plating of tumor components on the subcutaneous expanses of young mice. J Exp Med (115): 1211–1230, 1962.
Prehn RT: Analysis of antigenic heterogeneity within individual 3-methylcholanthrene-induced mouse sarcomas. J Natl Cancer Inst (45): 1039–1044, 1970.
Byers WS, Johnston JO: Antigenic differences among osteogenic sarcoma tumor cells taken from different locations in human tumors. Cancer Res (37): 3173–3183, 1977.
Pimm MV, Baldwin RW: Antigenic heterogeneity of primary and metastatic tumors and its implications for immunotherapy. In: Grundmann E (ed) Metastatic tumor growth. Stuttgart, Gustav Fischer Verlag, 1980, pp 305.
Pimm MV, Embleton MJ, Baldwin RW: Multiple antigenic specificities within primary 3-methylcholanthrene-induced rat sarcomas and metastases. Int J Cancer (25): 621–629, 1980.
Kerbel RS: Implications of immunological heterogeneity of tumors. Nature (280): 358–360, 1979.
Albino AP, Lloyd KO, Houghton AN, Oettgen HF, Old LJ: Heterogeneity in surface antigen and glycoprotein expression of cell lines derived from different melanoma metastases of the same patient. J Exp Med (154): 1764–1778, 1981.
Miller FR, Heppner GH: Immunologic heterogeneity of tumor cell subpopulations from a single mouse mammary tumor. JNCI (63): 1457–1463, 1979.
Killion JJ, Kollmorgen GM: Isolation of immunogenic tumor cells by cell-affinity chromatography. Nature (259): 674–676, 1976.
Killion JJ: Immunotherapy with tumor subpopulations. I. Active, specific immunotherapy of L1210 leukemia. Cancer Immunol Immunother (4): 115–119, 1978.
Fogel M, Gorelik E, Segal S, Feldman M: Differences in cell surface antigens of tumor metastases and those of the local tumor. JNCI (62): 585–588, 1979.
Fuji H, Mihich E: Selection for high immunogenicity in drug resistant sublines of murine lymphomas demonstrated by plaque assay. Cancer Res (35): 946–952, 1975.
Schirrmacher V, Bosslet K, Shantz G, Clauer K, Hubsch D: Tumor metastases and cell-mediated immunity in a model system in DBA/2 mice. IV. Antigenic differences between a metastasizing variant, and the parental tumor line revealed by cytotoxic T lymphocytes. Int J Cancer (23): 245–252, 1979.
Fuji H, Mihich E, Pressman D: Differential tumor immunogenicity of L1210 and its sublines. J Immunol (119): 983–986, 1977.
Gorelick E, Fogel M, Segal S, Feldman M: Tumorassociated antigenic differences between the primary and distant metastatic tumor populations J Supramol Struct (12): 385–402, 1979.
Olsson L, Kiger N, Kronstrom H: Sensitivity of cloned high and low-metastatic murine Lewis lung tumor cells to lysis by cytotoxic autoreactive cells. Cancer Res (41): 4706–4709, 1981.
Nicolin A, Canti G, Marelli O, Veronese F, Goldin A: Chemotherapy and immunotherapy of L1210 leukemic mice with antigenic tumor sublines. Cancer Res (41): 1358–1362, 1981.
Bosslet K, Schirrmacher V: Escape of metastasizing clonal tumor cell variants from tumor-specific cytolytic T lymphocytes. J Exp Med (154): 557–562, 1981.
Bosslet K, Schirrmacher V: High-frequency generation of new immunoresistant tumor variants during metastasis of a cloned murine tumor line. Int J Cancer (29): 195–202, 1982.
Olsson L, Ebbesen P: Natural polyclonality of spontaneous AKR leukemia and its consequence for so-called specific immunotherapy. JNCI (62): 623–627, 1979.
McCune CS, Schapira DV, Henshaw EC: Specific immunotherapy of advanced renal carcinoma: evidence for the polyclonality of metastases. Cancer (47): 1984–1987, 1981.
Barranco SC, Haenelt BR, Gee EL: Differential sensitivities of five rat hepatoma cell lines to anticancer drugs. Cancer Res (38): 656–660, 1978.
Hakansson L, Trope C: On the presence within tumors of clones that differ in sensitivity to cytostatic drugs. Acta Pathol Microbiol Scand [A] (82): 35–40, 1974.
Hakansson L, Trope C: Cell clones with different sensitivity to cytostatic drugs in methylcholanthrene-induced mouse sarcomas. Acta Pathol Microbiol Scand [A] (82): 41–47, 1974.
Trope C: Different sensitivity to cytostatic drugs of primary tumor and metastasis of the Lewis lung carcinoma. Neoplasma (22): 171–180, 1975.
Lotan R, Nicolson GL: Heterogeneity in growth inhibition by β-trans-retinoic acid of metastatic B16 melanoma clones and in vivo selected cell variant lines. Cancer Res (39): 4767–4771, 1979.
Heppner GH, Dexter DL, DeNucci T, Miller FR, Calabresi P: Heterogeneity in drug sensitivity among tumor cell subpopulations of a single mammary tumor. Cancer Res (38): 3758–3763, 1978.
Barranco SC, Ho D, Derwinko B, Romsdahl MM, Humphrey RM: Differential sensitivities of human melanoma cells grown in vitro to arabinosylcytosine. Cancer Res (32): 2733–2736, 1972.
Barranco SC, Derwinko B, Humphrey RM: Differential response by human melanoma cells to 1,2-bis-(2-chloroethyl)-1-nitrosourea and bleomycin. Mutat Res (19): 277–280, 1973.
Lotan R: Different susceptibilites of human melanoma and breast carcinoma cell lines to retinoic acid-induced growth inhibition. Cancer Res (39): 1014–1019, 1979.
Trope C, Hakansson L, Dencker H: Heterogeneity of human adenocarcinomas of the colon and the stomach as regards sensitivity to cytostatic drugs. Neoplasma (22): 423–430, 1975.
Trope C: Different susceptibilities of tumor cell subpopulations to cytotoxic agents. In: Fidler IJ, White RJ (eds) Design of models for testing cancer chemotherapeutic agents. New York, D. Van Nostrand Co., 1982, pp 64–79.
Trope C, Aspergen K, Kullander S, Astredt B: Heterogeneous response of disseminated human ovarian cancers to cytostasis in vitro. Acta Obstet Gynecol Scand (58): 543–546, 1979.
Siracky J: An approach to the problem of heterogeneity of human tumor-cell populations. Br J Cancer (39): 570–577, 1979.
Baylin SB: Clonal selection and heterogeneity of human solid neoplasms. In: Fidler IJ, White RJ (eds) Design of models for testing cancer therapeutic agents. New York, D Van Nostrand Co, 1982, pp 50–63.
Biorklund A, Hakansson L, Stenstarn B, Trope C: Heterogeneity of non-Hodgkin's lymphomas as regards sensitivity to cytostatic drugs. Eur J Cancer (16): 654–657, 1980.
Baylin SB, Weisburger WR, Eggleston JC, Mendelshon G, Bearnen MA, Abeloff MD, Ettinger DS: Variable content of histaminase, L-dopa decarboxylase and calcitonin in small-cell carcinoma of the lung. Biologic and clinical implications. N Engl J Med (299): 105–110, 1978.
Tsuruo T, Fidler IJ: Differences in drug sensitivity among tumor cells from parental tumors, selected variants, and spontaneous metastases. Cancer Res (41): 3058–3064, 1981.
DeWys WD: Studies correlating the growth rate of a tumor and its metastases and providing evidence for tumor-related systemic growth-retarding factors. Cancer Res (32): 374–379, 1972.
Cifone MA, Kripke ML, Fidler IJ: Growth rate and chromosome number of tumor cell lines with different metastatic potential. J Supramol Struct (11): 467–476, 1979.
Cifone MA, Fidler IJ: Correlation of patterns of anchorage-independent growth with in vivo behavior of cells from a murine fibrosarcoma. Proc Natl Acad Sci USA (77): 1039–1043, 1980.
Miller BE, Miller FR, Leith J, Heppner GH: Growth interaction in vivo between tumor subpopulations derived from a single mouse mammary tumor. Cancer Res (40): 3977–3981, 1980.
Soule HB, Maloney T, McGrath CM: Phenotypic variance among cells isolated from spontaneous mouse mammary tumors in primary suspension culture. Cancer Res (41): 1154–1164, 1981.
Zupi G, Mauro F, Sacchi A: Cloning in vitro and in vivo of Lewis lung carcinoma: properties and characteristics. Br J Cancer (41): 309–310, 1981.
Talmadge JE, Starkey JR, Stanford DR: In vitro characteristics of metastatic variant subclones of restricted genetic origin. J Supramol Struct (15): 139–152, 1981.
Danielson KG, Anderson LW, Hosick HL: Selection and characterization in culture of mammary tumor cells with distinctive growth properties in vivo. Cancer Res (40): 1812–1819, 1980.
Rabotti G: Ploidy of primary and metastatic human tumours. Nature (183): 1276–1277, 1959.
Ito E, Moore GE: Characteristic differences in clones isolated from an S37 ascites tumor in vitro. Exp Cell Res (48): 440–447, 1967.
Mittleman F: The chromosomes of fifty primary Rous rat sarcomas. Hereditas (69): 155–186, 1971.
Ohno S: Genetic implication of karyological instability of malignant somatic cells. Physiol Rev (51): 496–526, 1971.
Bohm N, Sondritter W: DNA in human tumors: a cytophotometric study. Curr Top Pathol (60): 152–219, 1975.
Straus MJ: In: Straus MJ (ed) Lung cancer. New York, Grune and Stratton, 1977, pp 19–32.
Vindelov LV: Flow microfluorometric analysis of nuclear DNA in cells from solid tumors and cell suspensions. Cell Pathol (24): 227–242, 1977.
Shapiro JR, Yung W, Shapiro WR: Isolation, karyotype and clonal growth of heterogeneous subpopulations of human malignant gliomas. Cancer Res (41): 2349–2359, 1981.
Vindelov LV, Hansen HH, Christensen IJ, Spang-Thomsen M, Hirsch FR, Hansen M, Nissen NI: Clonal heterogeneity of small-cell anaplastic carcinoma of the lung demonstrated by flow cytometric DNA analysis. Cancer Res (40): 4295–4300, 1980.
Tilley WD, Keightley DD, Cant ELM: Intersite variation of α estrogen receptors in human breast cancer. Br J Cancer (38): 544–546, 1978.
Dexter DL, Kowalski HM, Blazer BA, Fligiel Z, Vogel R, Heppner GH: Heterogeneity of tumor cells from a single mouse mammary tumor. Cancer Res (38): 3174–3181, 1978.
Kusyk CJ, Seski JC, Medlin WV, Edwards CL: Progressive chromosome changes associated with different sites of one ovarian carcinoma. INCI (66): 1021–1025, 1981.
Fidler IJ, Gruys E, Cifone MA, Barnes Z, Bucana C: Demonstration of multiple phenotypic diversity in a murine melanoma of recent origin. JNCI (67): 947–956, 1981.
Niles RM, Makarski JS: Hormonal activation of adenylate cyclase in mouse melanoma metastatic variants. J Cell Physiol (96): 355–359, 1978.
Tao TW, Burger MM: Nonmetastasizing variants selected from metastasizing melanoma cells. Nature (270): 437–438, 1977.
Brunson KW, Nicolson GL: Selection and biologic properties of malignant variants of a murine lymphosarcoma. JNCI (61): 1499–1503, 1978.
Raz A, McLellan WE, Hart IR, Bucana CD, Hoyer LC, Sela BA, Dragsten P, Fidler IJ: Cell surface properties of B16 melanoma variants with differing metastatic potential. Cancer Res (40): 1645–1651, 1980.
Reading CL, Belloni DN, Nicolson GL: Selection and in vivo properties of lectin-attachment variants of malignant murine lymphosarcoma cell lines. JNCI (64): 1241–1249, 1980.
Franks LM, Estrogen-treated prostatic cancer. Cancer (13): 490–501, 1960.
Sluyser M, Evers SG, DeGoey CC: Sex hormone receptors in mammary tumours of GR mice. Nature (263): 386–389, 1976.
Sluyser M, Van Nie R: Estrogen receptor content and hormone-responsive growth of mouse mammary tumors. Cancer Res (34): 3252–3257, 1974.
Brennan MJ, Donegan WL, Appleby DE: The variability of estrogen receptors in metastatic breast cancer. Am J Surg (137): 260–262, 1979.
Isaacs JT, Wake N, Coffey DS, Sandberg AA: Genetic instability coupled to clonal selection as a mechanism for tumor progression in the Dunning R-3327 rat prostatic adenocarcinoma system. Cancer Res (42): 2353–2361, 1981.
Isaacs JR, Coffey DS: Adaptation versus selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation therapy as studied in the Dunning R-3327H adenocarcinoma. Cancer Res (41): 5070–5075, 1981.
Semple TV, Moore GE, Morgan RT, Woods LK, Quinn LA: Multiple cell lines from patients with malignant melanoma: morphology, karyology and biochemical analysis. JNCI (68): 365–371, 1982.
Kiricuta I, Mustea I, Rogozaw I, Simu G: Relations between tumor and metastases. I. Aspects of the crabtree effect. Cancer (68): 365–371, 1982.
Baylin SB, Abeloff MD, Wieman KC, Tomford JW, Ettinger DS: Elevated histaminase (diamine oxidase) activity in small-cell carcinoma of the lung. N Engl J Med (293): 1286–1290, 1975.
Lavner EH, Rutherford CL: Implementation of micromethods to resolve problems of human breast tumor heterogeneity in analysis of cyclic 3′: 5′ nucleotide phosphodieiterase. Cancer Res (42): 1661–1668, 1982.
Angello JC, Danielson KG, Anderson LW, Hosick HL: Glycosaminoglycan synthesis by subpopulations of epithelial cells from a mammary adenocarcinoma. Cancer Res (42): 2207–2210, 1982.
Willis RA: The mode of origin of tumours (fields of origin of epithelial tumours). In: Willis RA (ed) Pathology of tumors. London, Butterworth, 1960, p 108.
Foulds L: The experimental study of tumor progression: a review. Cancer Res (14): 327–339, 1954.
Reddy AL, Fialkow PJ: Multicellular origin of fibrosarcomas in mice induced by the chemical carcinogen 3-methylcholanthrene. J Exp Med (150): 878–886, 1980.
Tanouka H, Tanaka K: Evidence for single cell origin of 3-methylcholanthrene-induced fibrosarcomas in mice with cellular mosaicism. Cancer Res (42): 1856–1858, 1982.
Fialkow PJ: Use of genetic markers to study cellular origin and development of tumors in human females. Adv Cancer Res (15): 191–226, 1972.
Fialkow PJ: Clonal origin of human tumors. Biochim Biophys Acta (458): 283–310, 1976.
Nowell PS: The clonal evolution of tumor cell subpopulations. Science (194): 23–28, 1976.
Barrett CJ, Ts'o POP: Evidence for the progressive nature of neoplastic transformation in vitro. Proc Natl Acad Sci USA (75): 3761–3765, 1978.
Iannaccone PM, Gardner RL, Harris H: The cellular origin of chemically induced tumors. J Cell Sci (29): 249–255, 1978.
Rubin H: Is somatic mutation the major mechanism of malignant transformation? JNCI (64): 995–1000, 1980.
Klein E: Gradual transformation of solid into ascites tumors. Permanent difference between the original and the transformed sublines. Cancer Res (14): 482–485, 1954.
Klein E: Gradual transformation of solid into ascites tumors. Evidence favoring the mutation-selection theory. Exp Cell Res (8): 188–212, 1955.
Potter VR: Phenotypic diversity in experimental hepatomas: the concept of partially blocked ontogeny. Br J Cancer (1): 23–29, 1978.
Hager C, Miller FR, Heppner GH: Influence of serial transplantation on the immunological-clinical correlates of BALB/cf C3H mouse mammary tumors. Cancer Res (38): 2492–2498, 1978.
Hager JC, Russo J, Ceriani RL, Peterson JA, Fligiel S, Jolly G, Heppner GH: Epithelial characteristics of five subpopulations of a heterogeneous strain BALB/cf C3H mouse mammary tumor. Cancer Res (41): 1720–1730, 1981.
Loeb LA, Springate CG, Battula N: Errors in DNA replication as a basis of malignant changes. Cancer Res (34): 2311–2321, 1974.
Waren ST, Schultz RA, Chang C, Wade HJ, Trosko JE: Elevated spontaneous mutation rate in Bloom syndrome fibroblasts. Proc Natl Acad Sci USA (78): 3133–3137, 1981.
Cifone MA, Fidler IJ: Increasing metastatic potential is associated with increasing genetic instability of clones isolated from murine neoplasms. Proc Natl Acad Sci USA (78): 6949–6952, 1981.
Fidler IJ, Hart IR: Biological and experimental consequences of the zonal composition of solid tumors. Cancer Res (41): 3266–3267, 1981.
Koch FE: Zur frage der metastazenbildung bei Limpftumoren. Z Krebsforsch (48): 495–499, 1939.
Fidler IJ: Selection of successive tumor lines for metastasis. Nature (242): 148–149, 1973.
Fidler IJ, Kripke ML: Metastasis results from preexisting variant cells within a malignant tumor. Science (197): 893–895, 1977.
Kripke ML, Fidler IJ: Enhanced experimental metastasis of ultraviolet light-induced fibrosarcomas in ultraviolet light-irradiated syngeneic mice. Cancer Res (40): 625–629, 1980.
Kripke ML, Gruys E, Fidler IJ: Metastatic heterogeneity of cells from an ultraviolet light-induced murine fibrosarcoma of recent origin. Cancer Res (38): 2962–2967, 1978.
Fidler IJ, Hart IR: The origin of metastatic heterogeneity in tumors. Eur J Cancer (17): 487–494, 1981.
Tarin D, Price JE: Metastatic colonization potential of primary tumour cells in mice. Br J Cancer (39): 740–754, 1979.
Schmitt M, Daynes RA: Heterogeneity of tumorigenicity phenotype in murine tumors. I. Characterization of regressor and progressor clones isolated from a nonmutagenized ultraviolet regressor tumor. J Exp Med (153): 1344–1359, 1981.
Dexter DL, Kowalski HM, Blazar BA, Fligiel Z, Vogel R, Heppner GH: Heterogeneity of tumor cells from a single mouse mammary tumor. Cancer Res (38): 3174–3181, 1978.
Brattain MG, Fine WD, Khaled FM, Thompson J, Brattain DE: Heterogeneity of malignant cells from a human colonic carcinoma. Cancer Res (41): 1751–1758, 1981.
Stackpole CW: Distinct lung-colonizing and lung-metastasizing cell populations in B16 mouse melanoma. Nature (289): 798–800, 1981.
Suzuki N, Withers R, Koehler MW: Heterogeneity and variability of artificial lung colony-forming ability among clones from mouse fibrosarcoma. Cancer Res (38): 3349–3351, 1978.
Poste G, Fidler IJ: The pathogenesis of cancer metastasis. Nature (283): 139–146, 1980.
Briles EB, Kornfeld S: Isolation and metastatic properties of detachment variants of B16 melanoma cells. JNCI (60): 1217–1222, 1978.
Poste GH, Doll J, Hart IR, Fidler IJ: Selection of variant lines with increased invasive capacities. Cancer Res (40): 1636–1644, 1980.
Hart IR: Selection and characterization of an invasive variant of the B16 melanoma. Am J Pathol (97): 587–600, 1979.
Fidler IJ, Bucana C: Mechanism of tumor cell resistance to lysis by syngeneic lymphocytes. Cancer Res (37): 3945–3956, 1977.
Schirrmacher V, Bosslet K: Tumor metastases and cell-mediated immunity in a model system in DBA/2 mice. X. Immunoselection of tumor variants differing in tumor antigen expression and metastatic capacity. Int J Cancer (25): 781–788, 1980.
Frost PH, Kerbel RS: Immunoselection in vitro of a nonmetastatic variant from a highly metastatic tumor. In J Cancer (27): 381–385, 1981.
Talmadge JE, Meyers KM, Prieur DJ, Starkey JR: Role of NK cells in tumour growth and metastasis in beige mice. Nature (284): 622–624, 1980.
Hanna N, Fidler IJ: Relationship between metastatic potential and resistance to NK cell-mediated cytotoxicity in three murine tumor systems. JNCI (66): 1183–1190, 1981.
Gorelik E, Feldman M, Segal S: Selection of 3LL tumor subline resistant to natural effector cells concomitantly selected for increased metastatic potency. Cancer Immunol Immunother (12): 105–109, 1982.
Talmadge JE, Starkey JR, Davis WC, Cohen A: Introduction of metastatic heterogeneity by short term in vivo passage of a cloned transformation cell line. J Supramol Struct (120): 227, 1979.
Shearman PJ, Longenecker BM: Selection for virulence and organ-specific metastasis of Herpes virus-transformed lymphoma cells. Int J Cancer (25): 363–369, 1980.
Enders JF, Diamondopoulos FT: A study of variation and progression in oncongenicity in an SV 40-transformed hamster heart cell line and its clones. Proc Soc Biol (171): 431–443, 1969.
Talmadge JE, Fidler IJ: Cancer metastasis is either selective or random depending on the parent tumour population. Nature (289): 301–303, 1981.
Talmadge JE, Fidler IJ: Enhanced metastatic potential of tumor cells harvested from spontaneous metastases of heterogeneous murine tumors. JNCI (69): 975–980, 1982.
Talmadge JE, Key ME, Hart IR: Characterization of a murine ovarian reticulum cell sarcoma of histiocytic origin. Cancer Res (41): 1271–1280, 1981.
Hart IR, Talmadge JE, Fidler IJ: Metastatic behavior of murine reticulum cell sarcoma exhibiting organ-specific growth. Cancer Res (41): 1281–1287, 1981.
Neri A, Welch D, Kawaguchi T, Nicolson GL: Development and biologic properties of malignant cell sublines and clones of a spontaneously metastasizing rat mammary adenocarcinoma. JNCI (68): 507–517, 1982.
Raz A, Hanna N, Fidler IJ: In vivo isolation of a metastatic tumor cell variant involving selective and nonadaptive processes. JNCI (66): 183–189, 1981.
Nicolson GL, Custead SE: Tumor metastasis is not due to adaptation of cells to a new organ environment. Science (215): 176–178, 1982.
Mantovani A, Giavazzi R, Alessandri G, Spreafico F, Garattini S: Characterization of tumor lines derived from spontaneous metastases of a transplantable murine sarcoma. Eur J Cancer (17): 71–76, 1981.
Giavazzi R, Alessandri G, Spreafico F, Garattini S, Mantovani A: Metastasizing capacity of tumour cells from spontaneous metastases of transplanted murine tumours. Br J Cancer (42): 432–442, 1980.
Talmadge JE, Wolman S, Fidler IJ: Evidence for the clonal origin of spontaneous metastases. Science (217): 361–363, 1982.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Talmadge, J.E. The selective nature of metastasis. Cancer Metast Rev 2, 25–40 (1983). https://doi.org/10.1007/BF00046904
Issue Date:
DOI: https://doi.org/10.1007/BF00046904